Proteinuria should be used as a surrogate in CKD

Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


Surrogate end points of renal failure are instrumental to the testing of new treatments in patients with chronic kidney disease, the natural history of which is characterized by a slow, asymptomatic decline in renal function. The magnitude of proteinuria is widely recognized as a marker of the severity of glomerulopathy. Population-based studies have identified proteinuria as a predictor of future decline in glomerular filtration rate and of the development of end-stage renal disease. More importantly, a reduction in proteinuria invariably translates into a protection from renal function decline in patients with diabetic and nondiabetic renal disease with overt proteinuria. Thus, proteinuria should be considered a valuable surrogate end point for clinical trials in patients with proteinuric renal diseases.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalNature Reviews Nephrology
Issue number5
Publication statusPublished - May 2012

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Proteinuria should be used as a surrogate in CKD'. Together they form a unique fingerprint.

Cite this